Extended Data Fig. 8: The integrin α2β1–CXCL1 and lytC_22–Slamf4 axis function independently.
(a-c) 5×105 MC38 cells were subcutaneously injected into C57BL/6 J mice (n = 6). After 6 days, mice were injected with P. anaerobius or lytC_22 intratumorally and followed by PD1 mAb treatment. 100ug anti-PD1 intraperitoneally and 50ug anti-Slamf4 antibody intravenously injected every 3 days. a. Schematic diagram of experimental design (left) and representative images of tumours (right). b. Gzmb+CD8+T cells in tumours from different groups. 6 mice were used in each group. c. CXCL1 level in tumour tissue were detected using ELISA. 4-5 mice were used in each group including n = 4 mice in Ctrl, lytC_22, Ctrl+a-Slamf4, lytC_22+a-Slamf4 and n = 5 mice in PA, PA + a-Slamf4 group. d. Schematic diagram of experimental design. CRC cell line (Caco-2, HCT116) pretreated with 20ug/ml anti-Slamf4 antibody, followed by P. anaerobius infection. Then culture medium was collected. e. Quantification of secreted CXCL1 from human CRC cells Caco-2, HCT116 treated with vehicle or P. anaerobius after blocking Slamf4 receptor. PBS (n = 3), PA (n = 4), PBS+a-Slamf4 (n = 3), PA + a-Slamf4 (n = 3). f. Schematic diagram of experimental design. Human CRC cell line (Caco-2, HCT116) and mouse CRC cell line (MC38) pretreated with 1 mM RGDS peptide, followed by P. anaerobius infection. Then culture medium was collected and condensed using 50 kDa protein concentration column. g. Quantification of secreted lytC_22 from P. anaerobius was detected using western blot. Data are presented as mean ± SEM. P values were calculated by one-way ANOVA followed by Fisher’s LSD test (b) and one-way ANOVA followed by Tukey’s post-hoc test (c, e).
